Loading...
XNAS
KRMD
Market cap203mUSD
Jul 09, Last price  
4.43USD
1D
0.00%
1Q
5.23%
Jan 2017
786.00%
Name

KORU Medical Systems Inc (Pre-Reincorp)

Chart & Performance

D1W1MN
XNAS:KRMD chart
P/E
P/S
4.95
EPS
Div Yield, %
Shrs. gr., 5y
1.95%
Rev. gr., 5y
11.21%
Revenues
41m
+22.23%
1,734,5792,347,6783,439,1103,774,8734,920,7236,390,5347,763,9538,698,85211,244,66012,247,33812,293,65515,976,67217,353,73723,162,62124,176,44823,490,17527,896,03728,517,66633,646,46341,127,366
Net income
-3m
L-56.52%
-254,721-2,4991,030,855889,444704,085815,893725,763703,429753,117782,864-535,0001,085,948910,570564,349-1,212,063-4,562,823-8,661,142-13,741,062-6,066,633-2,637,926
CFO
462k
P
-85,591117,614528,180382,2981,028,465560,601784,790954,388826,0991,914,813-331,616899,9121,479,662320,620-743,323-4,319,510-5,404,549-4,892,553-319,718462,405

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
IPO date
Oct 27, 1993
Employees
85
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑02
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT